A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

Overview of attention for article published in British Journal of Haematology, July 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 2 news outlets
blogs: 1 blog

twitter: 9 X users

Readers on

mendeley: 43 Mendeley

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 33,490 followers.

RT @gedefo_sefh: A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zo…

A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma https://t.co/9LOgO544O6

https://t.co/BHJHeeUA8S Correspondence with the editor office is a refreshing experience. BTKi clearly has activity in MZL. Surprised it is not available in England. @BritSocHaem @AstraZeneca

RT @graham74GC: Acalabrutinib in marginal zone lymphoma • 43pts, 1+ prior lines • med FU 13.3mo • ORR 53%, CRR 13% • est med PFS 27.4mo • A…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.